🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

#NewProfilePic

As we consider the future of cell & gene therapies, strategies that use transient cell alterations, like our approach at SQZBiotech, could potentially provide durable patient benefit without long-term safety concerns. My latest article in Cell&Gene: cellandgene.com/doc/rethinking…

👏👏👏

Learn more about the science behind SQZBiotech’s NIH grant to develop a novel cell therapy for the potential treatment of #Parkinsonsdisease in this #HCW episode on regenerative medicine approaches:

Preclinical data published in Frontiers - Immunology by SQZBiotech demonstrated that Tolerizing Antigen Carriers (TACs) can induce multiple key mechanisms of antigen-specific tolerance and potentially protect against #Type1diabetes investors.sqzbiotech.com/news/news-deta… Cc @JDRF #celltherapy

At #AACR22, SQZBiotech will present a poster on the SQZ® eAPC platform and a Trial-in-Progress presentation on our SQZ® AAC candidate: investors.sqzbiotech.com/posters-and-pu… Cc City of Hope

At #AACR22 we're sharing preclinical data on our eAPC platform demonstrating that our multiplexed mRNA engineering of immune cells increased CD8 T cell activity and could potentially increase the number of patients who could benefit from the therapy: investors.sqzbiotech.com/news/news-deta…

.U.S. FDA has granted Fast Track Designation to our lead APC candidate, SQZ-PBMC-HPV, for HPV16+ advanced or metastatic solid tumors, creating the potential to bring this important new therapy to patients earlier. Learn more: investors.sqzbiotech.com/news/news-deta…

This Thursday, SQZ CEO & Founder Armon Sharei will participate in a panel on Scientific Innovation: Transferring Technology from Academia as part of Longwood Healthcare Leaders Spring MIT web conference. Learn more: longwoodhealthcareleaders.com/spring2022

Thrilled to announce a new collaboration with STEMCELL Technologies to co-develop a research-use-only microfluidic intracellular delivery system. With the RUO system, our goal is to help drive #celltherapy development in the broader scientific community: investors.sqzbiotech.com/news/news-deta…

Today at #ASGCT22 we share preclinical data that shows that our SQZ® Point-of-Care manufacturing system could produce our Activating Antigen Carrier (AAC) therapeutic candidate in under 6 hours: buff.ly/3LqIu2P #celltherapy

Traditional cell engineering methods often permanently alter cells. In this #HCW episode, learn how transient approaches can create powerful therapeutics without permanently changing the cell – potentially broadening disease applicability & reducing long-term safety risks:

We are incredibly excited to welcome Marshelle Smith Warren, MD, as our Chief Medical Officer. Her cell-based therapeutic development experience and global clinical trial background will strengthen our ability to execute on our mission for patients: investors.sqzbiotech.com/news/news-deta…

A new article in Nature Medicine highlights Armon Sharei's discovery of our Cell Squeeze® technology and its potential to provide a new method of drug delivery for autoimmune and infectious diseases: nature.com/articles/s4159…

June is #CancerImmunotherapyMonth. At SQZ Biotech, we recognize the powerful potential of the immune system. Learn more about how we are putting patients’ immune systems to work to fight against their cancer: sqzbiotech.com/patients/

Thank you to our SQZ social committee for organizing an awesome event to celebrate #PrideMonth!

At #FOCIS2022 we share preclinical data showing SQZ® TACs led to the presentation of antigen associated w/#celiacdisease, supporting our T cell tolerizing approach. This will support our planned TAC IND submission for celiac disease in the 1st half of 2023 buff.ly/3zP7aQ7

Go SQZBiotech !

PacBio was once Illumina's acquisition target. Now it's become a competitor. Jared Whitlock reports on how the sequencing market is evolving: endpts.com/pacbio-once-sl…

#esgctcellfiecontest